These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 30942881)
41. Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. Moore DJ; Jain S; Dubé MP; Daar ES; Sun X; Young J; Corado K; Ellorin E; Milam J; Collins D; Blumenthal J; Best BM; Anderson P; Haubrich R; Morris SR Clin Infect Dis; 2018 May; 66(10):1566-1572. PubMed ID: 29228144 [TBL] [Abstract][Full Text] [Related]
42. Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis. Ibrahim ME; Castillo-Mancilla JR; Yager J; Brooks KM; Bushman L; Saba L; Kiser JJ; MaWhinney S; Anderson PL AIDS Res Hum Retroviruses; 2021 Jun; 37(6):421-428. PubMed ID: 33191774 [TBL] [Abstract][Full Text] [Related]
43. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. Yager JL; Brooks KM; Castillo-Mancilla JR; Nemkov C; Morrow M; Peterson S; Ibrahim M; Bushman L; Kiser JJ; MaWhinney S; Anderson PL AIDS; 2021 Dec; 35(15):2481-2487. PubMed ID: 34482350 [TBL] [Abstract][Full Text] [Related]
44. Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy. Frasca K; Morrow M; Coyle RP; Coleman SS; Ellison L; Bushman LR; Kiser JJ; Zheng JH; Mawhinney S; Anderson PL; Castillo-Mancilla J J Antimicrob Chemother; 2019 May; 74(5):1395-1401. PubMed ID: 30668713 [TBL] [Abstract][Full Text] [Related]
45. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? Adams JL; Sykes C; Menezes P; Prince HM; Patterson KB; Fransen K; Crucitti T; De Baetselier I; Van Damme L; Kashuba AD J Acquir Immune Defic Syndr; 2013 Mar; 62(3):260-6. PubMed ID: 23111578 [TBL] [Abstract][Full Text] [Related]
46. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. Celum CL; Gill K; Morton JF; Stein G; Myers L; Thomas KK; McConnell M; van der Straten A; Baeten JM; Duyver M; Mendel E; Naidoo K; Dallimore J; Wiesner L; Bekker LG J Int AIDS Soc; 2020 Nov; 23(11):e25636. PubMed ID: 33247553 [TBL] [Abstract][Full Text] [Related]
47. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis. Havens PL; Tamhane A; Stephensen CB; Schuster GU; Gordon CM; Liu N; Wilson CM; Hosek SG; Anderson PL; Kapogiannis BG; Mulligan K AIDS Res Hum Retroviruses; 2019 Feb; 35(2):123-128. PubMed ID: 30280906 [TBL] [Abstract][Full Text] [Related]
48. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons. Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902 [TBL] [Abstract][Full Text] [Related]
49. Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring. Niu X; Kubiak RW; Siriprakaisil O; Klinbuyaem V; Sukrakanchana PO; Cressey R; Okochi H; Gandhi M; Cressey TR; Drain PK Open Forum Infect Dis; 2022 Aug; 9(8):ofac405. PubMed ID: 36004315 [TBL] [Abstract][Full Text] [Related]
50. Acceptability and Feasibility of Providing Adherence Feedback Based on Tenofovir Diphosphate in Dried Blood Spots: Results from a Pilot Study Among Patients and Providers in Cape Town, South Africa. Ferraris CM; D'avanzo PA; Jennings L; Robbins RN; Nguyen N; Leu CS; Dolezal C; Mgbako O; Hsiao NY; Joska J; Castillo-Mancilla JR; Myer L; Anderson PL; Belaunzarán-Zamudio PF; Mellins CA; Orrell C; Remien RH AIDS Behav; 2023 Oct; 27(10):3478-3486. PubMed ID: 37043053 [TBL] [Abstract][Full Text] [Related]
51. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study. Grant RM; Pellegrini M; Defechereux PA; Anderson PL; Yu M; Glidden DV; O'Neal J; Yager J; Bhasin S; Sevelius J; Deutsch MB Clin Infect Dis; 2021 Oct; 73(7):e2117-e2123. PubMed ID: 32766890 [TBL] [Abstract][Full Text] [Related]
52. Comparing Predictive Ability of Two Objective Adherence Measures in a Community-Based Cohort on Antiretroviral Therapy in South Africa: Tenofovir Diphosphate Concentrations and Electronic Adherence Monitors. Jennings L; Ferraris CM; Castillo-Mancilla JR; Robbins RN; Nguyen N; Leu CS; Dolezal C; Hsiao NY; Mgbako O; Joska J; Myer L; Anderson PL; Remien RH; Orrell C; J Acquir Immune Defic Syndr; 2023 Aug; 93(4):327-332. PubMed ID: 36976520 [TBL] [Abstract][Full Text] [Related]
53. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514 [TBL] [Abstract][Full Text] [Related]
54. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ; Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303 [TBL] [Abstract][Full Text] [Related]
55. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548 [TBL] [Abstract][Full Text] [Related]
56. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155 [TBL] [Abstract][Full Text] [Related]
57. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers. Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713 [TBL] [Abstract][Full Text] [Related]
59. Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment. Ellsworth GB; Burke LA; Wells MT; Mishra S; Caffrey M; Liddle D; Madhava M; O'Neal C; Anderson PL; Bushman L; Ellison L; Stein J; Gulick RM J Acquir Immune Defic Syndr; 2021 Jan; 86(1):73-80. PubMed ID: 33306564 [TBL] [Abstract][Full Text] [Related]
60. Associations Between Tenofovir Diphosphate in Dried Blood Spots, Impaired Physical Function, and Fracture Risk. Abdo M; Coyle RP; Seifert SM; Castillo-Mancilla JR; Jankowski CM; Mawhinney S; Anderson PL; Erlandson KM Open Forum Infect Dis; 2021 Jan; 8(1):ofaa577. PubMed ID: 33447638 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]